A patient with chronic liver disease was treated with large doses of meben dazole for a hepatic hydatid cyst. Eighteen days after beginning treatment he developed marrow aplasia which reverted to normal after the drug was stopped. This is the sixth patient described as developing marrow aplasia when treated with large doses of meben dazole. We suggest that the aplasia is related to the dose ofthe drug, and that the patient's chronic liver disease was an important factor in its genesis. Patients treated with large doses of mebendazole should have their blood counts monitored during treatment.
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Mebendazole is a broad spectrum anthel mintic drug which, in low doses, has been used a great deal with few adverse effects. ' Reported cases ofneutropenia due to mebendazole in English language literature penia after treatment with large doses of meben dazole. The data which suggest the drug as the cause ofmarrow aplasia in our patient are: 1) the appearance of anemia and leukopenia 18 days after the start oftreatment;
2) signs ofbone mar row toxicity manifested by hemorrhage and ede ma in the stroma; 3) remission 17 days after stopping treatment; and 4) the absence of other etiological factors. Our patient presented characteristics which were similar to those of the 5 cases previously described,@7 with the same changes in the mar row biopsy and the same latency period (Table   1) . We draw attention to the fact that this is the second patient with liver disease who has developed aplasia. We postulate that aplasia is dose-related since: 1) there have been no re ported instances of aplasia in any of the thou sands ofpatients with intestinal parasitosis treat ed with low doses of mebendazole (the most widely used schedule is 100â€"300 mg twice daily for 3 days); 2) it has appeared only in patients treated with large doses; and 3) it has been re versed in almost all of them. In the only case in which plasma levels of mebendazole were mea sured they were very high,7 giving further support to the hypothesis of dose-related toxicity. The chronic liver disease in our patient, with possible alteration in the metabolism ofmebendazole and thus a possible increase in its plasma levels, could be an important factor in the genesis ofthe apla sia.
In conclusion, we recommend frequent mon itoring ofblood counts during high dose meben dazole treatment, especially in patients with liver disease.
